溢多利 reported revenue of ¥0.40B for the period ended 2026-06-30, -4.4% year on year. Net income was ¥-0.00B, a -1.0% net margin on a 46.1% gross margin. The largest revenue line is 生物酶制剂 at 84% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.40B | -4.4% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | -127.0% |
| Gross margin | 46.1% | Net margin -1.0% |
| Revenue Q/Q | -13.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 生物酶制剂 | ¥0.33B | 84.3% |
| 植物提取物 | ¥0.04B | 9.1% |
| 饲料和饲料添加剂 | ¥0.02B | 5.7% |
| 其他产品 | ¥0.00B | 0.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.21B | 53.9% |
| R&D | ¥0.05B | 11.5% |
| SG&A | ¥0.13B | 32.9% |
| Tax & other | ¥0.00B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.81B |
| Total liabilities | ¥0.25B |
| Shareholders' equity | ¥2.57B |
| Equity / assets | 91.2% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | -459% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
斯莱克 ・ 光环新网 ・ 三联虹普 ・ ST雪浪 ・ 飞天诚信 ・ 富邦科技 ・ 节能国祯 ・ 艾比森 ・ 天华新能 ・ 中来股份 ・ 菲利华 ・ ST迪瑞
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies